Nitto Denko, Dainippon begin Phase II for world's first transdermal antipsychotic

Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea. The patch is the world's first transdermal patch formulation for the treatment of schizophrenia, according to Nitto Denko. Schizophrenia affects around 800,000 people in Japan, and the two companies have been working on the patch since 2010.

The Phase I studies in healthy people showed that blonanserin was well-absorbed in single and repeated doses. The Phase II trial is designed to identify the optimal dose, according to Nitto Denko's announcement.

- read the press release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…